Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | HTT | P42858 | 1/20 | 0.79 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.79 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.66 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riboprine SCHEMBL1763190 | 1.00 | TP53 (0.79) | TP53LMNAALOX15TSHRHTT | |
| Riboprine SCHEMBL16805426 | 1.00 | TP53 (0.79) | TP53LMNAALOX15TSHRHTT | |
| Riboprine SCHEMBL29552839 | 1.00 | TP53 (0.79) | TP53LMNAALOX15TSHRHTT | |
| Riboprine SCHEMBL18503566 | 1.00 | TP53 (0.79) | TP53LMNAALOX15TSHRHTT | |
| Riboprine SCHEMBL4815729 | 1.00 | TP53 (0.79) | TP53LMNAALOX15TSHRHTT | |
| Riboprine SCHEMBL18870819 | 1.00 | TP53 (0.79) | TP53LMNAALOX15TSHRHTT | |
| Riboprine SCHEMBL4600 | 1.00 | TP53 (0.79) | TP53LMNAALOX15TSHRHTT | |
| SCHEMBL25170535 | 0.99 | TP53 (0.78) | TP53LMNAALOX15TSHRHTT | |
| SCHEMBL31307032 | 0.99 | TP53 (0.78) | TP53LMNAALOX15TSHRHTT | |
| SCHEMBL8706995 | 0.99 | TP53 (0.78) | TP53LMNAALOX15TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11222 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| EP-4524131-A1 | SMALL MOLECULES FOR TREATING CANCER, INHABITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | AlonBio Ltd. (IL) | 2025-03-19 | — | — | EP | claimed |
| US-12202803-B2 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | ALONBIO LTD. (IL) | 2025-01-21 | — | — | US | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| US-12109219-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2024-10-08 | — | — | US | claimed |
| WO-2024162488-A1 | PHARMACEUTICAL COMPOSITION COMPRISING CUCURBITACIN D FOR PREVENTING OR TREATING NEUROPATHIC PAIN | 주식회사 재인알앤피 | 2024-08-08 | — | — | WO | claimed |
| EP-4401780-A1 | AMORPHOUS PHOTOSENSITIZING PARTICLES, METHODS FOR THE PREPARATION THEREOF, AND METHODS FOR THE USE THEREOF | University of Maryland, College Park (US) | 2024-07-24 | — | — | EP | claimed |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2024-05-02 | — | — | US | claimed |
| CN-1634584-A | Anti-cancer medicine composition containing antimetabolite | SHANDONG LANJIN BIOENGINEERING (CN) | 2005-07-06 | — | — | CN | claimed |
| US-20050042327-A1 | Methods and compositions for increasing fermentation of a microorganism | VDF FUTURECEUTICALS | 2005-02-24 | — | — | US | claimed |
| WO-2004048447-A2 | CONTROLS AND STANDARDS FOR ASSAYS AND METHOD FOR MANUFACTURE THEREOF | AGDIA, INC. (US) | 2004-06-10 | — | — | WO | claimed |
| US-20040101972-A1 | Controls and standards for assays and method for manufacture thereof | AGDIA, INC. | 2004-05-27 | — | — | US | claimed |
| US-20040092583-A1 | Treatment for inhibiting neoplastic lesions | SHANAHAN-PRENDERGAST ELIZABETH (IE) | 2004-05-13 | — | — | US | claimed |
| EP-1351678-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | Shanahan-Prendergast, Elizabeth (IE) | 2003-10-15 | — | — | EP | claimed |
| EP-0855375-B9 | Use of adenine derivatives for systemically enhancing the migration and distribution of nutrients in plants | ENGRAIS COMPOSES MINERAUX ET A (FR) | 2002-09-25 | — | — | EP | claimed |
| WO-2002053138-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | SHANAHAN-PRENDERGAST ELISABETH (IE) | 2002-07-11 | — | — | WO | claimed |
| EP-0855375-B1 | Use of adenine derivatives for systemically enhancing the migration and distribution of nutrients in plants | ENGRAIS COMPOSES MINERAUX ET A (FR) | 2001-09-19 | — | — | EP | claimed |
| EP-0855375-A2 | Use of adenine derivatives for systemically enhancing the migration and distribution of nutrients in plants | SOCIETE D'ENGRAIS COMPOSES MINERAUX ET AMENDEMENTS (S.E.C.M.A.) (FR) | 1998-07-29 | — | — | EP | claimed |